News | Cath Lab | May 19, 2017

TherOx Completes Enrollment in IC-HOT Study of Supersaturated Oxygen Therapy System

Study of 100 patients will evaluate ability of next-generation TherOx system to improve acute myocardial infarction outcomes

TherOx Completes Enrollment in IC-HOT Study of Supersaturated Oxygen Therapy System

May 19, 2017 — TherOx Inc. announced that it completed enrollment in the IC-HOT (Evaluation of Intracoronary Hyperoxemic Oxygen Therapy) study. IC-HOT is a confirmatory study of the second-generation TherOx system that delivers supersaturated oxygen (SSO2) therapy for reduction of infarct size after an acute myocardial infarction (AMI).

The IC-HOT study enrolled 100 patients and is being conducted to support a premarket approval submission to the U.S. Food and Drug Administration (FDA). The primary study objective is to collect confirmatory data supporting the safety and effectiveness of SSO2 therapy in treatment of anterior AMI patients who have undergone successful percutaneous coronary intervention (PCI) with stenting within six hours of experiencing AMI symptoms.

“Since the advent of angioplasty and stenting to treat heart attack we haven't seen any new treatment options to reduce infarct size in this vulnerable population, and SSO2 therapy appears to fulfill this unmet need,” said Nainesh Patel, M.D., interventional cardiologist at Lehigh Valley Health Network and an investigator for the study.

According to the American Heart Association, every year nearly 1 million people in the United States have heart attacks. Although PCI is the standard of care in treating AMI, for many patients it doesn’t do enough to reduce infarct size and achieve maximum clinical benefit.

"SSO2 gherapy treats patients who have experienced the most serious large anterior wall heart attacks — patients who often have poor outcomes even after successful intervention,” said Frances Wood, M.D., interventional cardiologist at WakeMed Heart and Vascular - Structural Heart and study investigator. “This therapy is a promising new tool to reduce infarct size and thus improve outcomes for these higher risk patients.”

SSO2 therapy is intended to provide interventional cardiologists with the first treatment option beyond PCI to salvage heart muscle in heart attack patients. In SSO2 therapy, the patient’s blood is supersaturated with oxygen and then returned directly to the targeted ischemic area of the heart through a small catheter. Adjunctive to PCI, SSO2 therapy is intended to salvage the jeopardized myocardium and thus reduce infarct size. Multiple peer-reviewed studies have demonstrated the infarct size reduction achieved by SSO2 therapy was clinically significant compared to PCI alone.

For more information: www.therox.com

Related Content

New Multi-Center Research Effort to Focus on Early Life Origins of Heart Health
News | Congenital Heart| June 23, 2017
Heart health in children will be the focus of three closely synergistic research projects and an integrated...
Sponsored Content | Videos | Angiography| June 22, 2017
Shimadzu Medical Systems hghlighted new features of its Trinias Interventional X-ray line at the America College of C
Pacemakers and Other Cardiac Devices Can Help Solve Forensic Cases
News | Pacemakers| June 20, 2017
Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented at the European...
BioTrace Medical's Tempo Lead Shows Stability and Safety in Real-World Performance
News | Leads Implantable Devices| June 20, 2017
BioTrace Medical Inc. announced that the company’s Tempo Temporary Pacing Lead was featured in an oral presentation and...
BioImage-2 Study to Investigate Atherosclerotic Disease Progression
News | Cardiovascular Ultrasound| June 20, 2017
Mount Sinai Heart and BioImage-2 LLC recently announced the start of the BioImage-2 study investigating the progression...
Stroke2prevent Receives FDA 510(k) Clearance for A-View
Technology | Ultrasound Transesophageal echo (TEE)| June 20, 2017
June 20, 2017 — Dutch medical device company Stroke2prevent BV recently announced it has received U.S.
IABP recall for Maquet, Datascope intra-aortic balloon pump CS100 and CS300

The Datascope CS300 IABP console.

News | Hemodynamic Support Devices| June 20, 2017
June 20, 2017 — The U.S.
Sponsored Content | Videos | Cardiovascular Ultrasound| June 15, 2017
Madhav Swaminathan, M.D., FASC, FAHA, clinical director of cardiothoracic anesthesiology, at Duke Univer
radial access, transradial access trial using anticoagulants
News | Radial Access| June 15, 2017
June 15, 2017 — In patients undergoing t...
Overlay Init